IBRX · ImmunityBio, Inc.

ImmunityBio’s Q1 2026 results reflect strong top-line execution offset by substantial non-cash accounting impacts. Net product revenue surged to $44.2 million — a 168% year-over-year increase — driven by expanding ANKTIVA unit sales (up 168% YoY) and broadening commercial access, including first-time regulatory approval in Asia (Macau) and commercial launch in Saudi Arabia. The Company highlighted continued adoption by new prescribers and expansion into maintenance settings, reinforcing demand durability. However, GAAP net loss ballooned to $632.8 million, primarily due to a $530.9 million non-cash charge from the change in fair value of warrant, derivative, and related-party convertible note liabilities — directly tied to a significant rise in ImmunityBio’s common stock price during the quarter. This volatility underscores the sensitivity of its financial statements to equity valuation swings, a structural feature of its capital structure. In contrast, adjusted net loss — which excludes these non-cash items plus stock-based compensation and a $7.4 million convertible note receivable write-off — rose only modestly to $86.2 million, reflecting disciplined underlying expense growth: R&D increased $19.8 million (to $68.0 million) and SG&A rose $13.1 million (to $45.8 million), both supporting clinical advancement and commercial scale. Critically, the Company ended the quarter with $380.9 million in cash and marketable securities — a $138.1 million sequential increase — providing ample liquidity to fund pivotal trials, including the fully enrolled BCG-naïve CIS trial (QUILT-2.005) and planned 2026 sBLA submission, while executing on global commercial expansion. Management emphasized a more experienced commercial organization entering Q2, positioning the company to sustain revenue growth even as it navigates complex financial reporting dynamics.